Regulation of T-cell function and autoimmune inflammation by deubiquitinase CYLD
去泛素酶 CYLD 对 T 细胞功能和自身免疫炎症的调节
基本信息
- 批准号:8289618
- 负责人:
- 金额:$ 48.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAnimal ModelAntigensAttenuatedAutoimmune ProcessAutoimmunityBiochemicalBone MarrowCD4 Positive T LymphocytesCell physiologyCellsChronicColitisComplicationCoupledDataDeubiquitinationDevelopmentDiseaseEnteralEnvironmental Risk FactorEventExperimental Autoimmune EncephalomyelitisFundingGene Expression RegulationGeneticHomeostasisHumanITGAM geneImmune System DiseasesImmune responseInfectionInflammationInflammatoryInflammatory Bowel DiseasesInflammatory disease of the intestineIntestinesKnock-outKnockout MiceKnowledgeLaboratoriesLeadLinkLymphocyteLysineMediatingMicrobeMolecularMusNF-kappa BNormal tissue morphologyOsteoclastsOsteopeniaOsteoporosisPatientsPhosphotransferasesPopulationProductionPublishingRag1 MouseRegulationRegulatory T-LymphocyteResearch Project GrantsRoleSeminalSignal TransductionSpleenT cell differentiationT cell responseT memory cellT-Cell ActivationT-LymphocyteTh1 CellsUbiquitinUbiquitinationWorkattenuationbasebonebone losscytokinedesignexperiencemacrophagemicrobialosteoclastogenesispreventpublic health relevanceresponsetherapy designtranscription factorubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): T cells effectively respond to foreign antigens but are tolerant to self-tissues and normal enteric flora. Inappropriate activation or differentiation of T cells can lead to severe immunological disorders, including autoimmunity and inflammation. Thus, a better understanding of the molecular mechanisms regulating T-cell activation and tolerance is important for rational design of therapies for immunological diseases. The overall objective of this application is to understand the molecular and cellular mechanisms by which a newly identified deubiquitinase (DUB), CYLD, regulates T-cell function and autoimmune inflammation. During the current funding period, we have made seminal findings that establish CYLD as a pivotal regulator of T-cell activation and autoimmune inflammation. CYLD-deficient T cells are hyper-responsive to TCR stimulation, and the CYLD knockout (CYLD-/-) mice spontaneously develop intestinal inflammation with major features of human inflammatory bowel disease (IBD). The CYLD-/- mice also experience severe bone loss, which is known as a major extra-intestinal complication of IBD and animal model of colitis. Moreover, our preliminary studies reveal that loss of CYLD renders mice hypersensitive to the induction of experimental autoimmune encephalomyelitis (EAE). Thus, CYLD is a master regulator of T-cell function and autoimmune inflammatory diseases. The studies proposed in this continuation application are based on strong preliminary and published data from our laboratory. In particular, we have shown that loss of CYLD in T cells causes constitutive activation of NF-kB, a transcription factor mediating T-cell activation and survival and being involved in many inflammatory disorders. The CYLD-/- T cells also display marked attenuation of the costimulatory molecule ICOS, which is crucial for the induction of T-cell tolerance and regulation of T-cell differentiation. Consistent with these molecular studies, we have found that the CYLD-/- T cells appear to be defective in tolerance to enteric microbes, since their adoptive transfer into lymphocyte-deficient Rag1-/- mice induces severe colitis. Furthermore, the CYLD-/- mice produce aberrantly high levels of inflammatory Th17 and Th1 cells, coupled with heightened EAE response. We have obtained preliminary evidence that CYLD regulates macrophage response to TLR-stimulated expression of a specific subset of cytokines known to regulate Th1 and Th17 differentiation. Based on these findings, we hypothesize that CYLD regulates key signaling events involved in T-cell activation and differentiation as well as tolerance induction. We will perform three specific aims to accomplish our overall objective. (1) Examine the molecular mechanism and functional significance of CYLD-mediated NF-kB regulation in T cells. (2) Characterize the molecular and cellular mechanisms by which CYLD regulate T-cell tolerance and inflammatory T-cell differentiation. (3) Examine the immunological and osteoclast-intrinsic mechanisms by which CYLD regulates bone erosion.
PUBLIC HEALTH RELEVANCE: T cells are vital for immune responses against microbial infections. However, deregulated T cell activation, due to genetic or environmental factors, can lead to severe immunological disorders, including autoimmunity and chronic inflammation. The focus of this research project is to understand how a deubiquitinase, CYLD, regulates T-cell activation and tolerance, thereby preventing the development of autoimmunity and inflammation. This knowledge is important for rational design of effective immunological therapies.
描述(由申请人提供):T细胞有效地对外国抗原做出反应,但对自我入狱和正常肠菌群具有耐受性。 T细胞的不当激活或分化会导致严重的免疫疾病,包括自身免疫性和炎症。因此,对调节T细胞激活和耐受性的分子机制的更好理解对于免疫疾病的理性设计很重要。该应用的总体目的是了解新鉴定的去泛素酶(DUB),CYLD,调节T细胞功能和自身免疫性炎症的分子和细胞机制。在当前的资金期间,我们进行了开创性的发现,以CYLD为T细胞激活和自身免疫性炎症的关键调节剂。 CYLD缺陷型T细胞对TCR刺激具有高反应性,CYLD基因敲除(CYLD - / - )小鼠自发发展肠道炎症,具有人类炎症性肠病(IBD)的主要特征。 CYLD - / - 小鼠还经历了严重的骨质流失,这被称为IBD的主要肠外并发症和结肠炎动物模型。此外,我们的初步研究表明,CYLD的丧失使小鼠对实验性自身免疫性脑脊髓炎(EAE)的诱导过敏。因此,CYLD是T细胞功能和自身免疫性疾病的主要调节剂。 在此连续应用中提出的研究基于我们实验室的强大初步和已发布的数据。特别是,我们已经表明,T细胞中CYLD的丧失会导致NF-KB的组成型激活,NF-KB是介导T细胞激活和存活的转录因子,并参与许多炎症性疾病。 CYLD - / - T细胞还显示了共刺激分子ICO的明显衰减,这对于诱导T细胞耐受性和T细胞分化的调节至关重要。与这些分子研究一致,我们发现CYLD - / - T细胞似乎在容忍肠性微生物方面有缺陷,因为它们的产卵转移到缺乏淋巴细胞的RAG1 - / - 小鼠中会诱导严重的结肠炎。此外,CYLD - / - 小鼠产生异常高的炎症性Th17和Th1细胞,并与EAE反应增强相结合。我们获得了初步证据,表明CYLD调节对TLR刺激的巨噬细胞反应,该表达的特定细胞因子已知的调节Th1和Th17分化的特定子集。基于这些发现,我们假设CYLD调节与T细胞激活和分化以及耐受性诱导有关的关键信号事件。我们将执行三个特定的目标来实现我们的整体目标。 (1)检查T细胞中CYLD介导的NF-KB调节的分子机制和功能意义。 (2)表征CYLD调节T细胞耐受性和炎症T细胞分化的分子和细胞机制。 (3)检查CYLD调节骨侵蚀的免疫学和破骨细胞内部机制。
公共卫生相关性:T细胞对于针对微生物感染的免疫反应至关重要。然而,由于遗传或环境因素而导致的失调的T细胞激活会导致严重的免疫疾病,包括自身免疫性和慢性炎症。该研究项目的重点是了解去泛素酶,CYLD如何调节T细胞激活和耐受性,从而防止自身免疫性和炎症的发展。这种知识对于有效的免疫疗法的合理设计很重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shao-Cong Sun其他文献
Shao-Cong Sun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shao-Cong Sun', 18)}}的其他基金
Molecular mechanisms underlying immunosuppression and inflammation caused by SARS-CoV2 proteins
SARS-CoV2蛋白引起免疫抑制和炎症的分子机制
- 批准号:
10163402 - 财政年份:2020
- 资助金额:
$ 48.88万 - 项目类别:
Molecular mechanisms regulating TLR signaling and inflammation
调节 TLR 信号传导和炎症的分子机制
- 批准号:
10265710 - 财政年份:2020
- 资助金额:
$ 48.88万 - 项目类别:
Signaling functions of Peli family of E3 ubiquitin ligases
E3 泛素连接酶 Peli 家族的信号传导功能
- 批准号:
8660625 - 财政年份:2013
- 资助金额:
$ 48.88万 - 项目类别:
Signaling functions of Peli family of E3 ubiquitin ligases
E3 泛素连接酶 Peli 家族的信号传导功能
- 批准号:
9044725 - 财政年份:2013
- 资助金额:
$ 48.88万 - 项目类别:
Signaling functions of Peli family of E3 ubiquitin ligases
E3 泛素连接酶 Peli 家族的信号传导功能
- 批准号:
8469642 - 财政年份:2013
- 资助金额:
$ 48.88万 - 项目类别:
Molecular Mechanisms Regulating Noncanonical NF-kB Signaling
调节非典型 NF-kB 信号传导的分子机制
- 批准号:
7807470 - 财政年份:2009
- 资助金额:
$ 48.88万 - 项目类别:
Signaling Functions of the Tumor Suppressor CYLD
肿瘤抑制因子 CYLD 的信号传导功能
- 批准号:
7150300 - 财政年份:2006
- 资助金额:
$ 48.88万 - 项目类别:
Signaling Functions of the Tumor Suppressor CYLD
肿瘤抑制因子 CYLD 的信号传导功能
- 批准号:
7247127 - 财政年份:2006
- 资助金额:
$ 48.88万 - 项目类别:
Regulation of T-cell function and autoimmune inflammation by deubiquitinase CYLD
去泛素酶 CYLD 对 T 细胞功能和自身免疫炎症的调节
- 批准号:
8046495 - 财政年份:2006
- 资助金额:
$ 48.88万 - 项目类别:
Signaling Functions of the Tumor Suppressor CYLD
肿瘤抑制因子 CYLD 的信号传导功能
- 批准号:
7493501 - 财政年份:2006
- 资助金额:
$ 48.88万 - 项目类别:
相似国自然基金
以C5aR为新型胞内共刺激分子增强CAR-T抗白血病的基础与临床研究
- 批准号:81870121
- 批准年份:2018
- 资助金额:55.0 万元
- 项目类别:面上项目
基于特异性肺癌新抗原的免疫疗法在动物模型上的疗效评估
- 批准号:81802263
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
滤泡辅助性T细胞在CTLA-4Ig诱导Graves病免疫耐受中的作用及机制研究
- 批准号:81801621
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
基于双靶分子识别的Dox调控的增强型IL13 CAR-T在恶性脑胶质瘤动物模型中的实验治疗研究
- 批准号:81773265
- 批准年份:2017
- 资助金额:50.0 万元
- 项目类别:面上项目
用于原发性肝癌治疗的嵌合抗原受体T细胞在动物模型上的研究
- 批准号:81472656
- 批准年份:2014
- 资助金额:71.0 万元
- 项目类别:面上项目
相似海外基金
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别:
Defining astrovirus-specific T cell responses
定义星状病毒特异性 T 细胞反应
- 批准号:
10667003 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别:
T cell/astrocyte fusions as a novel form of trained immunity to infection
T 细胞/星形胶质细胞融合作为一种新型的感染免疫训练形式
- 批准号:
10723089 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别:
T cell immunity in a rare juvenile form of motor neuron disease
一种罕见的青少年运动神经元疾病中的 T 细胞免疫
- 批准号:
10595316 - 财政年份:2023
- 资助金额:
$ 48.88万 - 项目类别: